Since the discovery of the cardiac hormone ANP by DeBold and coworkers in 1981, the field of natriuretic peptides has significantly advanced with translation of new knowledge to the clinical practice of heart failure (HF). This new knowledge has underscored the importance of cardio-renal mechanisms that contribute to optimal cardiovascular homeostasis. Work by others and the applicants have also established direct myocardial actions broadening their therapeutic potential beyond renal mechanisms. Most recently, BMP has been evaluated and approved as an intravenous therapy for symptomatic HF and as a diagnostic aid in HF. With the availability of new technologies, this field can be further advanced to provide additional knowledge with application to human cardiovascular disease. The broad objective of our application in experimental and human HF is to advance the cardiac peptide BNP as a novel therapeutic strategy for cardio-renal protection in progressive HF. The special focus on BNP is based upon significant progress during the current HL36634 funding period that recognizes the greater natriuretic action of BNP in HF compared to ANP and also importantly its anti-aldosterone and anti-fibrotic properties. Work by the applicants has also established unique hemodynamic actions in HF in which BNP enhances diastolic function and reduces left ventricular end systolic and diastolic volumes. Further, preliminary studies in advanced human HF support the possible presence of altered forms of circulating BNP with reduced biological action. Our specific goal is therefore to delay the progression of HF with novel chronic BNP based therapy through cardio-renal mechanisms. We will take a physiologic, genomic and proteomic approach in studies in large animal models of experimental HF and early and late stage human HF.
Our Specific Aims are as follows:
Aim 1 : To establish that chronic BNP delays the progression of experimental HF in the presence and absence of mineralocorticoid excess.
Aim 2 : To determine that the anti-fibrotic action of chronic BNP therapy also is independent of myocardial load.
Aim 3 : To determine the presence of altered forms of circulating BNP in early and late stage human HF.
Aim 4 : To determine the biological actions and binding properties of altered forms of circulating BNP in human HF in vitro and in vivo.
|Kawakami, Rika; Lee, Candace Y W; Scott, Christopher et al. (2018) A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure. Clin Pharmacol Ther 104:546-552|
|Ichiki, Tomoko; Dzhoyashvili, Nina; Burnett Jr, John C (2018) Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide. Int J Cardiol :|
|Chen, Yang; Burnett, John C (2018) Particulate Guanylyl Cyclase A/cGMP Signaling Pathway in the Kidney: Physiologic and Therapeutic Indications. Int J Mol Sci 19:|
|Lee, Candace Y W; Huntley, Brenda K; McCormick, Daniel J et al. (2016) Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions. Eur Heart J Cardiovasc Pharmacother 2:98-105|
|Meems, Laura M G; Burnett Jr, John C (2016) Innovative Therapeutics: Designer Natriuretic Peptides. JACC Basic Transl Sci 1:557-567|
|Holditch, Sara J; Schreiber, Claire A; Burnett, John C et al. (2016) Arterial Remodeling in B-Type Natriuretic Peptide Knock-Out Females. Sci Rep 6:25623|
|Ichiki, Tomoko; Huntley, Brenda K; Sangaralingham, S Jeson et al. (2015) Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides. JACC Heart Fail 3:715-23|
|Zakeri, Rosita; Burnett Jr, John C; Sangaralingham, S Jeson (2015) Urinary C-type natriuretic peptide: an emerging biomarker for heart failure and renal remodeling. Clin Chim Acta 443:108-13|
|Buglioni, Alessia; Burnett Jr, John C (2015) Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators. Clin Chim Acta 443:3-8|
|Miller, Wayne L; Borgeson, Daniel D; Grantham, J Aaron et al. (2015) Dietary sodium modulation of aldosterone activation and renal function during the progression of experimental heart failure. Eur J Heart Fail 17:144-50|
Showing the most recent 10 out of 241 publications